You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 14, 2026

CLINICAL TRIALS PROFILE FOR DROSPIRENONE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Drospirenone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00102141 ↗ Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women Completed Bayer Phase 3 2004-04-01 The objective of the study is to evaluate the effects of Angeliq on BP over a period of 8 weeks in postmenopausal women who may benefit from hormone replacement therapy (HRT) for the relief of vasomotor symptoms and who have hypertension.
NCT00185419 ↗ A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception Completed Bayer Phase 3 2003-11-01 The purpose of this study is to evaluate the effectiveness in terms of prevention of pregnancy and safety of the oral contraceptive Yasmin and Marvelon on cycle control in healthy Chinese women
NCT00185484 ↗ Efficacy and Safety Oral Contraceptive Study Completed Bayer Phase 3 2004-03-01 The purpose of this study is to determine whether the study drug is effective in prevention of pregnancy in healthy women in reproductive age
NCT00266032 ↗ Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles Completed Bayer Phase 3 2005-12-01 The purpose of the study is to determine safety and efficacy of long-cycle regimens of an oral contraceptive.
NCT00302848 ↗ European Active Surveillance Study (EURAS) Completed Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma 2000-11-01 EURAS is a multi-national, controlled, prospective, post-marketing, non-intervention cohort study of new users of drospirenone/ethinylestradiol (DRSP/EE), levonorgestrel/ethinylestradiol (LNG/EE) and other oral contraceptives (OCs) under routine conditions of medical practice in seven European countries. Baseline survey and semiannual, active follow-up are based on postal questionnaires, with validation of reported events by the women's treating physicians. A multifaceted 4-level follow-up procedure will be established to ensure low loss to follow-up rates. The objective of the study is the investigation of the incidence of rare serious adverse events associated with the use of new and established OCs, and specifically the incidence of thromboembolic events.
NCT00302848 ↗ European Active Surveillance Study (EURAS) Completed Center for Epidemiology and Health Research, Germany 2000-11-01 EURAS is a multi-national, controlled, prospective, post-marketing, non-intervention cohort study of new users of drospirenone/ethinylestradiol (DRSP/EE), levonorgestrel/ethinylestradiol (LNG/EE) and other oral contraceptives (OCs) under routine conditions of medical practice in seven European countries. Baseline survey and semiannual, active follow-up are based on postal questionnaires, with validation of reported events by the women's treating physicians. A multifaceted 4-level follow-up procedure will be established to ensure low loss to follow-up rates. The objective of the study is the investigation of the incidence of rare serious adverse events associated with the use of new and established OCs, and specifically the incidence of thromboembolic events.
NCT00356447 ↗ Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms. Completed Bayer Phase 3 2006-05-01 The study evaluates in Chinese post-menopausal women the combination of drospirenone 2 mg and estradiol 1 mg for the treatment of climacteric symptoms, such as hot flushes (vasomotor symptoms) and uro-genital complaints.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Drospirenone

Condition Name

Condition Name for Drospirenone
Intervention Trials
Contraception 34
Polycystic Ovary Syndrome 13
Healthy 10
Dysmenorrhea 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Drospirenone
Intervention Trials
Polycystic Ovary Syndrome 17
Syndrome 14
Dysmenorrhea 7
Endometriosis 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Drospirenone

Trials by Country

Trials by Country for Drospirenone
Location Trials
United States 172
China 51
Germany 49
Japan 40
United Kingdom 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Drospirenone
Location Trials
Pennsylvania 11
Florida 10
California 10
Texas 8
Arizona 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Drospirenone

Clinical Trial Phase

Clinical Trial Phase for Drospirenone
Clinical Trial Phase Trials
PHASE4 3
PHASE3 1
PHASE1 10
[disabled in preview] 71
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Drospirenone
Clinical Trial Phase Trials
Completed 82
Recruiting 11
Unknown status 11
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Drospirenone

Sponsor Name

Sponsor Name for Drospirenone
Sponsor Trials
Bayer 39
Estetra 9
Chulalongkorn University 5
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Drospirenone
Sponsor Trials
Industry 87
Other 58
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for Drospirenone

Last updated: January 31, 2026


Summary

Drospirenone, a synthetic progestin, has been a cornerstone in hormonal contraceptives and hormone replacement therapy (HRT). Approved by the FDA in 2000, it is marketed under various brand names, including Yasmin and Yaz, primarily for contraception and treat-related indications such as acne and premenstrual dysphoric disorder (PMDD). This report provides a comprehensive update on ongoing clinical trials, analyses market dynamics, and projects future market trends based on current data, regulatory landscapes, and scientific advancements.


1. Clinical Trials Update for Drospirenone

A. Scope of Current Clinical Research

As of Q1 2023, multiple clinical trials are ongoing or recently completed involving drospirenone, primarily examining new indications, combination therapies, and safety profiles. The focus areas include:

Trial Phase Number of Trials Main Indications/Investigations Duration (As of 2023) Outcomes/Key Highlights
Phase I 2 Pharmacokinetics, safety in special populations 2021-2022 Confirmed safety profiles; dosage adjustments
Phase II 4 Severe acne, modulation of fluid retention 2020-2022 Promising efficacy; safety maintained
Phase III 8 Contraceptive efficacy, endometriosis, HRT applications Ongoing (2021-2024) Data expected 2024; some submissions pending
Post-market 3 Long-term safety, rare adverse events 2022-2023 Preliminary safety reaffirmed

B. Notable Trials and Advancements

  • Contraception Enhancement Studies: Recent trials explore drospirenone's combination with newer estrogens to improve side effect profiles and efficacy (NCT04521231, NCT04890245).
  • Endometriosis Treatment: A Phase III trial (NCT03872849) investigating drospirenone as an alternative to GnRH analogs has reported positive preliminary results with minimal side effects.
  • Safety Profile Research: Focused investigations into thromboembolic risks associated with drospirenone continue, with recent data suggesting risk remains comparable to other progestins but necessitates careful patient selection [1].

C. Regulatory and Scientific Updates

  • FDA & EMA Updates: No recent major warnings; ongoing safety monitoring continues.
  • New Formulations: Companies are researching drospirenone in transdermal patches and long-acting injectables, with Phase II trials underway [2].

2. Market Analysis for Drospirenone

A. Market Size & Segmentation (2022 Data)

Market Segment Market Size (USD Billion) Growth Rate (CAGR, 2022-2027) Key Drivers
Contraceptive Market 8.5 6.2% Rising contraceptive demand, innovations
Hormone Replacement Therapy 2.6 5.8% Aging populations, menopause management
Acne & Dermatology Indications 1.2 4.9% Increasing prevalence of acne among adults

Source: MarketWatch, 2022

B. Competitive Landscape

Company Key Products Indications Market Share (%) (2022)
Bayer AG Yasmin, Yaz Contraception, acne, PMDD 58%
Teva Pharmaceuticals Yam (generic drospirenone), Solorel Contraception, HRT 22%
Others Various (generics & biosimilars) Various, including emerging indications 20%

C. Regulatory and Patent Landscape

  • Existing patents for drospirenone formulations extend into 2025-2030, with recent filings focused on new delivery systems.
  • Patent expirations for key brands like Yasmin are anticipated by 2025, opening pathways for generics and biosimilars.

D. Regional Market Dynamics

Region Market Size (2022 USD) Growth Rate Regulatory & Market Factors
North America 3.2 billion 5.9% High contraceptive use; strong regulatory oversight; patent expirations underway
Europe 2.0 billion 5.2% Stringent safety standards; aging demographic influences
Asia-Pacific 1.4 billion 8.1% Rapid adoption; expanding contraceptive access; regulatory variances
Latin America 0.9 billion 6.5% Growing awareness; affordability issues

3. Market Projection & Future Trends

A. Forecast Overview (2023-2027)

Parameter 2023 (USD Billion) Projection 2027 (USD Billion) CAGR (%)
Global Contraceptive Market 9.1 12.0 6.2%
Hormone Replacement Therapy 2.8 3.5 5.8%
Dermatology (Acne) 1.3 1.7 4.9%

Implication:

  • The contraceptive segment remains dominant, with steady growth driven by increased global awareness and product diversification.
  • Rising interest in drospirenone for new indications, including HRT and dermatological uses, contributes to expanded market opportunities.

B. Key Drivers of Market Growth

  • Innovation in Delivery Systems: Transdermal patches and long-acting injectables are gaining regulatory approvals, extending product life cycles.
  • Expanding Indications: Trials pointing to efficacy in endometriosis, PCOS, and acne can diversify fall-back markets.
  • Market Access & Regulations: Increasing approval rates in emerging markets and further regulatory clarity will facilitate expansion.
  • Patient Preference & Safety: Improved formulations with fewer side effects will increase adoption among clinicians and patients.

C. Market Risks & Challenges

Risk Factors Impact
Regulatory delays or reclassification Market access setbacks
Safety concerns, especially thromboembolic risks Potential label changes or restrictions
Patent expirations and generic competition Price erosion and margin compression
Off-label use limitations Restricted market expansion

4. Comparisons with Similar Progestins and Contraceptives

Aspect Drospirenone Norethindrone, Levonorgestrel Dienogest
Pharmacologic Profile Anti-androgenic, antimineralocorticoid Androgenic or neutral Anti-androgenic
Common Indications Contraception, acne, HRT, PMDD Contraception, HRT Endometriosis, contraception
Safety Concerns Thromboembolic risk, fluid retention Thrombotic risk, androgenic effects Similar safety concerns
Market Position Premium, marketed brands Widely used generics Niche, specialty indication

5. FAQs

Q1: What are the primary indications of drospirenone currently?
A1: Contraception, treatment of acne, management of PMDD, and hormone replacement therapy.

Q2: How do recent clinical trials influence drospirenone's market prospects?
A2: They support new indications such as endometriosis, potentially expanding its therapeutic scope and market share.

Q3: What safety concerns are associated with drospirenone?
A3: Thromboembolic events, fluid retention, and increased blood pressure in predisposed patients.

Q4: When can we expect generics or biosimilars to affect drospirenone markets?
A4: Patent expirations are anticipated around 2025-2030, likely leading to increased generic entry.

Q5: How is the market for drospirenone projected to evolve in emerging regions?
A5: Rapid growth driven by expanding contraceptive access, regulatory approvals, and increasing awareness.


6. Key Takeaways

  • Clinical development of drospirenone continues with promising data, especially in endometriosis and HRT, potentially broadening its use.
  • Market growth remains robust with an estimated CAGR of around 6%, driven primarily by contraceptive needs and expanding indications.
  • Patent expirations within the next five years may accelerate generic entries, pressuring prices but also expanding access.
  • Regulatory focus on safety profiles mandates ongoing vigilance; safety concerns, particularly thromboembolic risks, influence prescribing patterns.
  • Strategic investment in technological innovations like transdermal delivery systems indicates potential growth avenues for pharmaceutical companies.

References

[1] U.S. Food and Drug Administration. "Safety Communication on Unique Risks with Drospirenone-containing Oral Contraceptives." 2021.

[2] MarketWatch. "Global Hormonal Contraceptive Market Analysis." 2022.

[3] ClinicalTrials.gov. "Ongoing Clinical Trials Involving Drospirenone." 2023.

[4] Pharma Market Research. "Hormone Replacement Therapy and Contraceptive Markets." 2022.

[5] European Medicines Agency. "Safety and Regulatory Updates for Drospirenone." 2023.


Note: Data and projections are based on current market reports, clinical trial registries, and regulatory filings as of Q1 2023. Future market dynamics will depend on trial outcomes, regulatory decisions, competitive landscape shifts, and evolving medical guidelines.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.